PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

NCT03284723 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
95
Enrollment
INDUSTRY
Sponsor class

Stopped The trial was terminated based on the stage in drug development and assessment of PF-06804103 relative to the leading external competition. The decision was not due to a safety concern.

Conditions

Interventions

Sponsor

Pfizer